Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Medifast (MED) Net Margin (2016 - 2025)

Medifast's Net Margin history spans 16 years, with the latest figure at 24.12% for Q4 2025.

  • For Q4 2025, Net Margin fell 2477.0% year-over-year to 24.12%; the TTM value through Dec 2025 reached 4.84%, down 518.0%, while the annual FY2025 figure was 4.84%, 519.0% down from the prior year.
  • Net Margin reached 24.12% in Q4 2025 per MED's latest filing, down from 2.52% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 12.05% in Q1 2021 to a low of 24.12% in Q4 2025.
  • Average Net Margin over 5 years is 4.5%, with a median of 8.25% recorded in 2022.
  • The largest YoY upside for Net Margin was 718bps in 2025 against a maximum downside of -2477bps in 2025.
  • A 5-year view of Net Margin shows it stood at 9.0% in 2021, then decreased by -13bps to 7.86% in 2022, then crashed by -60bps to 3.16% in 2023, then tumbled by -79bps to 0.65% in 2024, then plummeted by -3804bps to 24.12% in 2025.
  • Per Business Quant, the three most recent readings for MED's Net Margin are 24.12% (Q4 2025), 2.52% (Q3 2025), and 2.34% (Q2 2025).